Research Capital analyst Andre Uddin maintained a “Speculative Buy” rating and C$0.70 target price on Theralase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback